Not medical advice. This website is not medical advice, a diagnosis, a match to a trial, or a recommendation to join a study. Listings are plain-English rewrites of public ClinicalTrials.gov records. Whether a site is still enrolling, and whether you qualify, can only be confirmed by the study team and your clinician. Source registry: ClinicalTrials.gov. Editorial rules: methodology.
RecruitingNot a traditional drug phaseobservationalRules rewrite
A Real-world Study in Participants With High-risk Non-Muscle-Invasive Bladder Cancer After Bacillus Calmett…
This study wants to assess participant's overall well-being and the extent to which medical services are used by participants with high-risk non-muscle-invasive bladder cancer (HR-NMIBC) who have received Bacillus Calmette-Guérin (BCG) therapy. HR-NMIBC is a type of bladder cancer in which cancer is confined to the inner lining of the bladder and has a high risk of returning or becoming more serious.
This is an observational study. You are not assigned a new experimental drug. Researchers measure what already happens in your care or in daily life.
Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.
What the registry says happens
This listing is observational (StudyType). The registry does not assign a new experimental drug as the study intervention.
They plan to enroll about 1 people at Suwon. Taking part typically means study visits and measurements plus check-ins.
Official title (unrewritten)
A Real-world Study to Describe the Patient Journey, Treatment Patterns, and Outcomes of Patients With High-risk Non-Muscle-Invasive Bladder Cancer After Bacillus Calmette-Guérin Therapy in Korea Using HIRA Claims Data
Primary outcome (registry wording): Percentage of Participants Receiving Bacillus Calmette-Guérin (BCG) Induction and Maintenance Therapy
Who it is for (from inclusion criteria)
Ages 18 Years to any
Confirmed diagnosis of bladder cancer (BC) based on International Classification of Diseases, 10th Revision (ICD-10) codes (C67 or D090) and cancer-specific insurance code V193 within the patient identification period of September 1, 2015, to August 31, 2024
Two outpatient or one inpatient visit anytime during the study period for bladder cancer
Received intravesical Bacillus Calmette-Guérin (BCG) following the qualifying transurethral resection of bladder tumor (TURBT). The date of first BCG instillation serves as the index date
No evidence of bladder cancer diagnosis, intravesical chemotherapy, or BCG in the 5-year look-back period prior to the qualifying TURBT, to ensure an incident BC definition
Who the registry excludes
Evidence of metastatic disease based on confirmed diagnosis (ICD-10: C77-C80) on or before index TURBT, or within 30 days after the index TURBT
Evidence of confirmed cancer diagnosis other than bladder cancer (ICD-10: C00-C76, C81-C97, excluding C67) on or before the index TURBT
Evidence of systemic treatments or radical cystectomy within 30 days after index TURBT
Less than 12 months of potential follow-up to the data cutoff after the index date (including patients with a claims-inactivity-based death proxy within 12 months from the index date)
Background: The National Cancer Institute Surgery Branch (NCI-SB) has developed experimental therapies that involve taking white blood cells from patients' tumor or from their blood, growing them in the laboratory in large numbers, and then giving the cells back to the patient. Objective: This study will allow patients to under screening and evaluation for participation in NC-SB Protocols.
Selected individuals suspected of having or with prior biopsy proof of malignant disease will be seen in the Urologic Oncology Branch, NCI. Blood samples may be collected at the time of the initial visit and at periodic intervals during the course of the disease.
This phase II trial studies how well cabozantinib works in combination with nivolumab and ipilimumab in treating patients with rare genitourinary (GU) tumors that has spread from where it first started (primary site) to other places in the body. Cabozantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
The sponsor posted status “Recruiting” on ClinicalTrials.gov at last ingest. Sites can pause independently. Confirm with the official record and the listed contact.
What phase is NCT07735793?
Not a traditional drug phase. Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.
Can PlainTrials tell me if I qualify for NCT07735793?
No. The inclusion and exclusion lists on this page are readable extracts of the public eligibility block. Only the study team can screen you.